Carboxymethylcellulose

Identification

Name

Carboxymethylcellulose

Accession Number

DB11059

Type

Small Molecule

Groups

Approved, Investigational

Description

Carboxymethylcellulose is a cellulose derivative that consists of the cellulose backbone made up of glucopyranose monomers and their hydroxyl groups bound to carboxymethyl groups. It is added in food products as a viscosity modifier or thickener and emulsifier. It is also one of the most common viscous polymers used in artificial tears, and has shown to be effective in the treatment of aqueous tear-deficient dry eye symptoms and ocular surface staining ¹. The viscous and mucoadhesive properties as well as its anionic charge allow prolonged retention time in the ocular surface ¹. Sodium carboxymethylcellulose is the most commonly used salt.

Synonyms

• Carbose
• Carboxymethyl cellulose
• Carmellose
• Carmelosa
• Cellulose carboxymethyl ether
• Cellulose gum
• Cellulose, carboxymethyl ether
• Thylose

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Carboxymethylcellulose sodium	K679OBS311	9004-32-4	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Unlock Additional Data
Acne Pimple Master Patch	Patch	30 mg/10g	Topical	Cosrx Inc.	2015-12-28	2015-12-31
Artificial Tears	Solution / drops	10 mg/1mL	Ophthalmic	Aru Pharma Inc.	2018-01-22	Not applicable
Biolle Gel Tears	Solution / drops	10 mg/1mL	Ophthalmic	Sage Ethnographic Research, Dba Biollé	2015-06-01	Not applicable
Biolle Tears	Solution / drops	5 mg/1mL	Ophthalmic	Sage Ethnographic Research, Dba Biollé	2015-06-01	Not applicable
Carboxymethylcellulose sodium	Solution	5 mg/1mL	Ophthalmic	Promed Exports Private Limited	2009-10-01	Not applicable
CareOne Lubricant	Solution / drops	5 mg/1mL	Ophthalmic	Foodhold U.S.A.	2017-05-18	Not applicable
CareOne Lubricant Eye Plus	Solution / drops	0.5 g/100mL	Ophthalmic	American Sales Company	2013-06-20	Not applicable
Cellufresh Liq 0.5%	Liquid		Ophthalmic	Allergan	1992-12-31	2000-06-01
Cho-A Derm	Dressing	130 g/433g	Topical	Cho-A Pharm.Co.,Ltd.	2018-06-19	Not applicable
CMC Lubricant Eye Drops	Solution / drops	5 mg/1mL	Ophthalmic	Amerisource Bergen	2013-03-22	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Clear Eyes for Dry Eyes	Carboxymethylcellulose sodium (1.0 %) + Glycerin (0.25 %)	Solution	Ophthalmic	Prestige Brands Inc	2008-03-26	2014-03-20
CVS Moisturizing Lubricating Eye	Carboxymethylcellulose sodium (5 mg/100mg) + Glycerin (9 mg/100mg)	Solution / drops	Ophthalmic	CVS Health	2013-09-03	Not applicable
CVS Moisturizing Lubricating Eye Twin Pack	Carboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL)	Solution / drops	Ophthalmic	CVS Health	2014-07-10	Not applicable
Equate Comfort	Carboxymethylcellulose sodium (2.5 mg/1mL) + Hypromellose (3 mg/1mL)	Gel	Ophthalmic	Walmart Stores	2014-04-10	Not applicable
Equate Day and Night Restore Tears	Carboxymethylcellulose sodium (5 mg/1mL) + Mineral oil (425 mg/1g) + Petrolatum (573 mg/1g)	Kit	Ophthalmic	Walmart Stores	2018-06-01	Not applicable
Equate Lubricating Eye	Carboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL)	Solution / drops	Ophthalmic	Walmart Stores	2012-04-01	Not applicable
Equate Restore Dual Lubricating	Carboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL)	Solution / drops	Ophthalmic	Walmart	2018-03-01	Not applicable
Equate Restore Dual Sensitive Lubricant	Carboxymethylcellulose sodium (5 mg/1mL) + Glycerin (9 mg/1mL)	Solution / drops	Ophthalmic	Walmart Stores	2016-05-03	Not applicable
Genteal Geldrops	Carboxymethylcellulose sodium (0.25 %) + Hypromellose (0.3 %)	Solution	Ophthalmic	Alcon, Inc.	2007-01-03	2014-01-13
GenTeal Moderate to Severe	Carboxymethylcellulose sodium (2.5 mg/1mL) + Hypromellose (3 mg/1mL)	Gel	Ophthalmic	Novartis	2009-09-14	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Acne Pimple Master Patch	Carboxymethylcellulose sodium (30 mg/10g)	Patch	Topical	Cosrx Inc.	2015-12-28	2015-12-31
Cho-A Derm	Carboxymethylcellulose sodium (130 g/433g)	Dressing	Topical	Cho-A Pharm.Co.,Ltd.	2018-06-19	Not applicable
Mizon Bye Bye Pimple	Carboxymethylcellulose (1.05 g/3.5g)	Patch	Topical	Mizon Co.,Ltd.	2018-05-01	Not applicable
Trouble Clear Spot	Carboxymethylcellulose sodium (36.87 mg/241)	Patch	Topical	Skinfood Co., Ltd.	2016-04-01	2017-03-01
Trouble Clear Spot 0.7cm	Carboxymethylcellulose sodium (6.17 mg/101)	Patch	Topical	Skinfood Co., Ltd.	2015-02-01	2017-03-01
Trouble Clear Spot 1.0cm	Carboxymethylcellulose sodium (12.58 mg/51)	Patch	Topical	Skinfood Co., Ltd.	2015-02-01	2017-03-01
Trouble Clear Spot 1.2cm	Carboxymethylcellulose sodium (18.12 mg/91)	Patch	Topical	Skinfood Co., Ltd.	2015-02-01	2017-03-01

Categories

• Anorexigenic Agents & Respiratory and CNS Stimulants
• Artificial Tears
• Biopolymers
• Bulk-Forming Laxatives
• Carbohydrates
• Carboxymethylcellulose Sodium
• Cellulose
• Compounds used in a research, industrial, or household setting
• EENT Drugs, Miscellaneous
• Gastrointestinal Agents
• Glucans
• Laxatives
• Macromolecular Substances
• Polymers
• Polysaccharides

UNII

05JZI7B19X

CAS number

9000-11-7

Pharmacology

Indication

Indicated for the symptomatic relief of burning, irritation and discomfort of the eyes due to dryness or exposure to wind or sun.

Pharmacodynamics

In a randomized clinical study of patients with mild or moderate forms of eye dryness, ophthalmic treatment with sodium carboxymethylcellulose resulted in a diminished frequency of symptoms compared to the placebo group ². Carboxymethylcellulose interacts with human corneal epithelial cells to facilitate corneal epithelial wound healing and attenuate eye irritation in a dose-dependent manner ¹. It exhibits protective actions on the ocular surface in various applications; it mediates cytoprotective effects on the ocular surface when applied prior to contact lenses and reduces the incidence of epithelial defects during LASIK ¹.

Mechanism of action

Carboxymethylcellulose binds to the surface of corneal epithelial cells via its glucopyranose subunits binding to glucose receptors GLUT-1 ¹. The residence time of carboxymethylcellulose bound to corneal cells is approximately 2 hours as indicated by a short-term binding assay ¹. Binding of carboxymethylcellulose to the matrix proteins stimulated corneal epithelial cell attachment, migration, and re-epithelialization of corneal wounds ¹.

Target	Actions	Organism
USolute carrier family 2, facilitated glucose transporter member 1	binder	Humans

Unlock Additional Data

Additional Data Available

Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more

Additional Data Available

Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more

Additional Data Available

Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more

Absorption

No pharmacokinetic data available.

Volume of distribution

No pharmacokinetic data available.

Protein binding

No pharmacokinetic data available.

Metabolism

No pharmacokinetic data available.

Route of elimination

No pharmacokinetic data available.

Half life

No pharmacokinetic data available.

Clearance

No pharmacokinetic data available.

Toxicity

Rat oral LD50, rabbit dermal LD50, and rat inhalation LC50 of sodium carboxymethyl cellulose are 27000 mg/kg, >2 g/kg, and >5800 mg/m^3 (4 hours), respectively ^MSDS.

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• All Drugs
• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental

Drug	Interaction
Unlock Additional Data
Acetazolamide	The risk or severity of adverse effects can be increased when Acetazolamide is combined with Carboxymethylcellulose.
Aclidinium	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Aclidinium.
Agmatine	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Agmatine.
Alcuronium	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Alcuronium.
Alfentanil	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Alfentanil.
Alloin	The risk or severity of adverse effects can be increased when Carboxymethylcellulose is combined with Alloin.
Alphacetylmethadol	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Alphacetylmethadol.
Alphaprodine	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Alphaprodine.
Amantadine	The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Amantadine.
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Carboxymethylcellulose.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

Not Available

References

General References

1. Garrett Q, Simmons PA, Xu S, Vehige J, Zhao Z, Ehrmann K, Willcox M: Carboxymethylcellulose binds to human corneal epithelial cells and is a modulator of corneal epithelial wound healing. Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1559-67. doi: 10.1167/iovs.06-0848. [PubMed:17389485]
2. Bruix A, Adan A, Casaroli-Marano RP: [Efficacy of sodium carboxymethylcellulose in the treatment of dry eye syndrome]. Arch Soc Esp Oftalmol. 2006 Feb;81(2):85-92. [PubMed:16511715]

External Links

PubChem Substance

347911098

RxNav

2062

ChEMBL

CHEMBL1909054

Wikipedia

Carboxymethylcellulose

AHFS Codes

• 28:20.00 — Anorexigenic Agents & Respiratory and CNS Stimulants
• 52:13.00* — Artificial Tears
• 52:92.00 — EENT Drugs, Miscellaneous

MSDS

Download (34 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Other	Breast Cancer / Early Breast Cancer / Inflammatory carcinoma of the breast / Stage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Triple Negative Breast Cancer (TNBC) / Triple-Negative Breast Cancer (TNBC)	1
1	Active Not Recruiting	Treatment	Blasts 30 Percent or Less of Bone Marrow Nucleated Cells / Chronic Myelomonocytic Leukemia / High Risk Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Refractory Anemia	1
1	Completed	Treatment	Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22)	1
1	Completed	Treatment	Alkylating Agent-Related Acute Myeloid Leukemia / Chronic Myelomonocytic Leukemia / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Refractory Anemia With Excess Blasts in Transformation	1
1	Recruiting	Treatment	Prostate Cancer	1
1	Recruiting	Treatment	Recurrent Glioblastoma	1
1, 2	Completed	Treatment	Adult Brain Glioblastoma / Glioblastoma Multiforme (GBM)	1
1, 2	Completed	Treatment	Corneal Graft Failure / Corneal Neovascularization	2
1, 2	Completed	Treatment	Melanoma	1
1, 2	Recruiting	Treatment	Fallopian Tube Carcinoma / Ovarian Carcinoma / Primary Peritoneal Carcinoma	1
1, 2	Suspended	Treatment	Platinum-Resistant Fallopian Tube Carcinoma / Platinum-Resistant Ovarian Carcinoma / Platinum-Resistant Primary Peritoneal Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma	1
2	Not Yet Recruiting	Treatment	Anatomic Stage IV Breast Cancer AJCC v8 / Estrogen Receptor Negative / HER2/Neu Negative / Metastatic Triple-Negative Breast Carcinoma / Progesterone Receptor Negative / Prognostic Stage IV Breast Cancer AJCC v8	1
2	Recruiting	Treatment	Dry Eye	1
2	Withdrawn	Treatment	Adenoviral Conjunctivitis	1
2, 3	Completed	Treatment	Conjunctivitis, Viral	1
2, 3	Completed	Treatment	Dry Eye	1
3	Completed	Treatment	Bilateral LASIK Surgery	1
3	Completed	Treatment	Contact Lens Lubrication	1
3	Completed	Treatment	Dry Eye Syndrome (DES)	1
3	Completed	Treatment	Dry Eye Syndromes	5
4	Completed	Treatment	Abortion induced / Cervical Preparation / Pain / Pregnancy Termination	1
4	Completed	Treatment	Cataracts / Dry Eye Syndromes	1
4	Completed	Treatment	Dry Eye Syndrome (DES)	1
4	Completed	Treatment	Dry Eye Syndromes	7
4	Completed	Treatment	Dry Eye Syndromes / Keratoconjunctivitis Sicca	2
4	Enrolling by Invitation	Treatment	Diabetic Macular Edema (DME) / Neovascular Age-Related Macular Degeneration / Retinal Vein Occlusion	1
4	Not Yet Recruiting	Prevention	Myopia	1
Not Available	Completed	Not Available	Dry Eye Syndrome (DES)	2
Not Available	Completed	Treatment	Dry Eye Syndrome (DES)	2
Not Available	Completed	Treatment	Tremor, Essential	1
Not Available	Terminated	Treatment	Oral Lichen Planus	1
Not Available	Withdrawn	Treatment	Corneas	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Patch	Topical	30 mg/10g
Solution / drops	Ophthalmic	10 mg/1mL
Solution	Ophthalmic	5 mg/1mL
Solution / drops	Ophthalmic	0.5 g/100mL
Liquid	Ophthalmic
Dressing	Topical	130 g/433g
Solution / drops	Ophthalmic	2.5 mg/1mL
Liquid	Ophthalmic	0.5 g/100mL
Solution / drops	Ophthalmic
Kit	Ophthalmic
Liquid	Intraocular	5 mg/1mL
Gel	Ophthalmic
Solution, gel forming / drops	Ophthalmic	0.5 g/100mL
Solution	Ophthalmic
Solution / drops	Ophthalmic	.5 g/100mL
Liquid	Ophthalmic	5 mg/1mL
Solution, gel forming / drops	Ophthalmic	.5 g/100mL
Solution	Ophthalmic	0.5 g/100mL
Patch	Topical	1.05 g/3.5g
Solution	Ophthalmic	0.5 %
Capsule	Oral
Paste	Oral; Topical
Gel	Ophthalmic	10 mg/1mL
Solution / drops	Ophthalmic	1 %
Solution	Ophthalmic
Solution	Ophthalmic	1 %
Emulsion	Ophthalmic
Solution / drops	Ophthalmic
Solution / drops	Ophthalmic	0.5 %
Solution / drops	Ophthalmic	5 mg/1mL
Kit; solution	Ophthalmic
Aerosol	Oral
Patch	Topical	36.87 mg/241
Patch	Topical	6.17 mg/101
Patch	Topical	12.58 mg/51
Patch	Topical	18.12 mg/91

Prices

Not Available

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	300	MSDS

Predicted Properties

Not Available

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Taxonomy

Classification

Not classified

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on December 03, 2015 09:51 / Updated on April 03, 2020 10:38